AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab (July 11, 2006). doi:10.1152/ajpendo.00171.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/6/E1228    most recent
00171.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zanchi, A.
Right arrow Articles by Burnier, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zanchi, A.
Right arrow Articles by Burnier, M.
Submitted on April 8, 2006
Accepted on July 6, 2006

The PPAR-{gamma} agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats

Anne Zanchi1*, Christine Perregaux1, Marc Maillard1, Daniel Cefai1, Juerg Nussberger2, and Michel Burnier1

1 Department of Medicine, CHUV, Lausanne, Division of Nephrology, Switzerland
2 Department of Medicine, CHUV, Lausanne, Angiology Unit, Switzerland

* To whom correspondence should be addressed. E-mail: azanchidel{at}hotmail.com.

Objectives: Glitazones are efficient insulin sensitizers that blunt the effects of angiotensin II (Ang II) in the rat. Sodium chloride is another important modulator of the systemic and renal effects of Ang II. Whether glitazones interfere with the interaction between sodium and the response to Ang II is not known. Therefore, we investigated the effects of pioglitazone on the relation between sodium and the systemic and renal effects of Ang II in rats. Methods: Pioglitazone, or vehicle were administered for 4 weeks to 8 week old obese Zucker rats. Animals were fed a normal sodium (NS) or a high sodium (HS) diet. Intravenous glucose tolerance tests, systemic and renal hemodynamic responses to Ang II and the renal Ang II binding and expression of AT1 receptors were measured. Results: Food intake and body weight increased whereas BP, heart rate, filtration fraction and insulin levels decreased significantly with pioglitazone in obese rats on both diets. Pioglitazone blunted the systemic response to Ang II and abolished the increased responsiveness to Ang II induced by a HS diet. Pioglitazone modified the renal hemodynamic response to changes in salt intake while maintaining a lower filtration fraction with angiotensin II perfusion. These effects were associated with a decrease in the number and expression of the Ang II AT1 receptor in the kidney. Conclusions: These data demonstrate that the PPAR-{gamma} agonist pioglitazone modifies the physiological relationship between sodium chloride and the response to Ang II in insulin resistant rats.




This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Zanchi, A. G. Dulloo, C. Perregaux, J.-P. Montani, and M. Burnier
Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E91 - E95.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.